Irritable Bowel Syndrome: Pathophysiology and Current Therapeutic Approaches

2016 ◽  
pp. 75-113 ◽  
Author(s):  
Michael Camilleri ◽  
Alexander C. Ford
Keyword(s):  
Irritable Bowel Syndrome ◽  
Therapeutic Approaches ◽  
Irritable Bowel

Novel therapeutic approaches in the treatment of irritable bowel syndrome

2007 ◽  
Vol 148 (20) ◽  
pp. 923-928 ◽  
Author(s):  
István Pregun ◽  
László Herszényi ◽  
Márk Juhász ◽  
Pál Miheller ◽  
Zsolt Tulassay
Keyword(s):  
Irritable Bowel Syndrome ◽  
Therapeutic Approaches ◽  
Irritable Bowel ◽  
Novel Therapeutic

Az irritábilis bél szindróma (IBS) kezelése a változatos tünetek, a társuló neuropszichiátriai kórképek miatt nem könnyű feladat. Bár számos, különböző támadáspontú szert alkalmazunk a betegség kezelésére, a mai napig kevés olyan gyógyszer van, amelynek hatékonyságáról, biztonságosságáról és tolerabilitásáról egyértelmű bizonyítékok állnak rendelkezésre. Az IBS multikauzális jellegéből adódóan a visceralis hiperszenzitivitással, a motilitással, az agy-bél tengely szabályozási zavaraival kapcsolatos kutatások eredményei, a folyamatokban központi szerepet játszó neurotranszmitterek, ezek receptorainak megismerése teremtette meg az új kezelési lehetőségek alapját. Bár napjainkban néhány gyógyszert (alosetron, tegaserod) már törzskönyveztek egyes országokban IBS-ben, az új készítményekkel kapcsolatban még több, nagy betegszámú vizsgálatra van szükség.

A review of irritable bowel syndrome and an update on therapeutic approaches

2008 ◽  
Vol 9 (7) ◽  
pp. 1129-1143 ◽  
Author(s):  
John T Bassett ◽  
Brooks D Cash
Keyword(s):  
Irritable Bowel Syndrome ◽  
Therapeutic Approaches ◽  
Irritable Bowel

scholarly journals The Evolving Role of Gut Microbiota in the Management of Irritable Bowel Syndrome: An Overview of the Current Knowledge

2020 ◽  
Vol 9 (3) ◽  
pp. 685 ◽  
Author(s):  
Amir Mari ◽  
Fadi Abu Baker ◽  
Mahmud Mahamid ◽  
Wisam Sbeit ◽  
Tawfik Khoury
Keyword(s):  
Irritable Bowel Syndrome ◽  
Current Knowledge ◽  
Gastrointestinal Disorder ◽  
Economic Effects ◽  
Therapeutic Approaches ◽  
High Prevalence ◽  
Attractive Option ◽  
Irritable Bowel ◽  
Substantial Morbidity

The intestinal microbiota is one of the most rapidly evolving areas in biology and medicine. Extensive research in the last decade has escalated our understanding of the role of the microbiota in the pathogenesis of several intestinal and extra-intestinal disorders. Marked by high prevalence, substantial morbidity, and enormous costs, irritable bowel syndrome (IBS) is an important chronic gastrointestinal disorder that is widely encountered by gastroenterologists. Despite advances in our understanding of its pathophysiology, curative interventions have yet to be discovered, and therapeutic approaches remain symptom-driven. Recently, accumulating evidence has enlightened the possible impact of an imbalanced gut microbiome in the pathogenesis of IBS. In fact, several studies have documented altered microbiota in patients, while others have shown that IBS severity was associated with a distinct microbiota signature. These findings may pave the way for the use of microbiota manipulation strategies as an attractive option for IBS management, and may have an essential role in efforts to reduce the societal and economic effects of this ever-growing disorder. In this review, we have outlined the results of the latest research on the association between microbiota and IBS and their implications for the clinical management of affected patients.

Su1988 Novel Therapeutic Approaches for Treatment of Irritable Bowel Syndrome Using the Multi-Herbal Drug STW 5

2012 ◽  
Vol 142 (5) ◽  
pp. S-554
Author(s):  
Karen Nieber ◽  
Ulrike Voss ◽  
Stefanie Hoser ◽  
Sebastian Michael ◽  
Heba Abdel-Aziz ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Herbal Drug ◽  
Therapeutic Approaches ◽  
Irritable Bowel ◽  
Novel Therapeutic

scholarly journals Neurotransmitter Dysfunction in Irritable Bowel Syndrome: Emerging Approaches for Management

2021 ◽  
Vol 10 (15) ◽  
pp. 3429
Author(s):  
Mónica Gros ◽  
Belén Gros ◽  
José Emilio Mesonero ◽  
Eva Latorre
Keyword(s):  
Irritable Bowel Syndrome ◽  
Visceral Pain ◽  
Gastrointestinal Disorder ◽  
Current Evidence ◽  
Therapeutic Approaches ◽  
Key Factor ◽  
Enhanced Expression ◽  
Increased Sensitivity ◽  
Irritable Bowel ◽  
High Affinity Choline Transporter

Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder whose aetiology is still unknown. Most hypotheses point out the gut-brain axis as a key factor for IBS. The axis is composed of different anatomic and functional structures intercommunicated through neurotransmitters. However, the implications of key neurotransmitters such as norepinephrine, serotonin, glutamate, GABA or acetylcholine in IBS are poorly studied. The aim of this review is to evaluate the current evidence about neurotransmitter dysfunction in IBS and explore the potential therapeutic approaches. IBS patients with altered colorectal motility show augmented norepinephrine and acetylcholine levels in plasma and an increased sensitivity of central serotonin receptors. A decrease of colonic mucosal serotonin transporter and a downregulation of α2 adrenoceptors are also correlated with visceral hypersensitivity and an increase of 5-hydroxyindole acetic acid levels, enhanced expression of high affinity choline transporter and lower levels of GABA. Given these neurotransmitter dysfunctions, novel pharmacological approaches such as 5-HT3 receptor antagonists and 5-HT4 receptor agonists are being explored for IBS management, for their antiemetic and prokinetic effects. GABA-analogous medications are being considered to reduce visceral pain. Moreover, agonists and antagonists of muscarinic receptors are under clinical trials. Targeting neurotransmitter dysfunction could provide promising new approaches for IBS management.

Motor and sensory function of the rectum in different types of irritable bowel syndrome

2001 ◽  
Vol 120 (5) ◽  
pp. A399-A399
Author(s):  
J STEENS ◽  
P SCHAAR ◽  
C LAMERS ◽  
A MASCLEE
Keyword(s):  
Irritable Bowel Syndrome ◽  
Sensory Function ◽  
Different Types ◽  
Irritable Bowel

How restrictive are Rome II criteria for the diagnosis of the irritable bowel syndrome (IBS)?

2001 ◽  
Vol 120 (5) ◽  
pp. A231-A231
Author(s):  
F MEARIN ◽  
X BADIA
Keyword(s):  
Irritable Bowel Syndrome ◽  
Rome Ii Criteria ◽  
Irritable Bowel

Rome I versus Rome II; Overlap in patients enrolled in tegaserod phase III clinical trials for irritable bowel syndrome (IBS)

2001 ◽  
Vol 120 (5) ◽  
pp. A284-A284
Author(s):  
B NAULT ◽  
S SUE ◽  
J HEGGLAND ◽  
S GOHARI ◽  
G LIGOZIO ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Irritable Bowel Syndrome ◽  
Phase Iii ◽  
Phase Iii Clinical Trials ◽  
Irritable Bowel ◽  
Rome I
Sign in / Sign up

Export Citation Format

Share Document